Literature DB >> 16034630

Downregulation of the expression of bone morphogenetic protein 7 in experimental pyelonephritis.

Nese Karaaslan Biyikli1, Halil Tugtepe, Fulya Cakalagaoglu, Arzu Ilki, Harika Alpay.   

Abstract

Bone morphogenetic protein 7 (BMP 7) is a member of the transforming growth factor (TGF) beta superfamily and is involved in regeneration, repair, and development of specific tissues, for example kidney, gut, lens, and skeleton. BMP 7 has emerged as a renotrophic factor and experimental studies have shown its protective role against fibrotic processes. Tubulointerstitial changes are present in the pyelonephritic kidney which progresses to fibrosis. Renal fibrosis may lead to significant morbidity in the form of hypertension, proteinuria, and loss of renal function. The objective of this study was to investigate BMP 7 expression in experimental acute and chronic pyelonephritis models. Eighteen Wistar rats were injected with 0.1 mL solution containing E. coli ATCC 25922 10(10) cfu mL(-1) into left renal medullae. Six rats were used as a sham group and were given 0.1 mL 0.9% NaCl. Pyelonephritic rats were sacrificed 24 h (group I, n=6), 1 week (group II, n=6), and 6 weeks (group III, n=6) after E. coli injection. Serum creatinine levels were analyzed. Renal tissues were studied histopathologically by use of hematoxylin and eosin and scored for diagnosis of pyelonephritis. BMP 7 expression was studied semiquantitatively by immunohistochemical staining. Acute (group I) and chronic (group II and group III) pyelonephritic histopathological changes were observed in experimental pyelonephritic groups. A gradual decrease in BMP 7 expression was observed in the tubulointerstitial and tubular area of the pyelonephritic kidneys, mildest in the acute pyelonephritic group and most severe in the chronic pyelonephritic 6th week group. A statistically significant difference was observed between tubulointerstitial BMP 7 expression by groups I and III (P=0.017) and by groups III and IV (P=0.000). Tubular BMP 7 expression was statistically significantly different between groups II and IV (P=0.009) and between groups III and IV (P=0.002). The data imply that BMP 7 has a major role in chronic pyelonephritis. Tubulointerstitial and tubular BMP 7 expression also had a significant negative correlation with fibrosis, tubular, atrophy, and vascular changes. Serum creatinine levels of the study group were all normal. We conclude that the decrease in renal BMP 7 expression in experimental chronic pyelonephritis is one of the factors responsible for fibrotic changes in persistent renal damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034630     DOI: 10.1007/s00467-005-1927-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  28 in total

1.  Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction.

Authors:  K A Hruska; G Guo; M Wozniak; D Martin; S Miller; H Liapis; K Loveday; S Klahr; T K Sampath; J Morrissey
Journal:  Am J Physiol Renal Physiol       Date:  2000-07

2.  Angiotensin II type 1 receptor antagonist (losartan) down-regulates transforming growth factor-beta in experimental acute pyelonephritis.

Authors:  A Khalil; K Tullus; M Bakhiet; L G Burman; G Jaremko; A Brauner
Journal:  J Urol       Date:  2000-07       Impact factor: 7.450

3.  Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney.

Authors:  M Simon; J G Maresh; S E Harris; J D Hernandez; M Arar; M S Olson; H E Abboud
Journal:  Am J Physiol       Date:  1999-03

4.  A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye.

Authors:  A T Dudley; K M Lyons; E J Robertson
Journal:  Genes Dev       Date:  1995-11-15       Impact factor: 11.361

5.  Microvascular changes in the early stage of reflux pyelonephritis. An experimental study in the pig kidney.

Authors:  P A Androulakakis; P G Ransley; R A Risdon; K Sorger; R Hohenfellner
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

6.  Etiology of chronic renal failure in Turkish children.

Authors:  A Sirin; S Emre; H Alpay; A Nayir; I Bilge; F Tanman
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

Review 7.  Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.

Authors:  Armando Luis Negri
Journal:  J Nephrol       Date:  2004 Jul-Aug       Impact factor: 3.902

8.  Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy.

Authors:  Song Wang; Qing Chen; Theodore C Simon; Frank Strebeck; Lala Chaudhary; Jeremiah Morrissey; Helen Liapis; Saulo Klahr; Keith A Hruska
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

Review 9.  Role of the renin-angiotensin system in disorders of the urinary tract.

Authors:  J W Brock; T E Hunley; M C Adams; V Kon
Journal:  J Urol       Date:  1998-11       Impact factor: 7.450

10.  Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat.

Authors:  S Vukicevic; V Basic; D Rogic; N Basic; M S Shih; A Shepard; D Jin; B Dattatreyamurty; W Jones; H Dorai; S Ryan; D Griffiths; J Maliakal; M Jelic; M Pastorcic; A Stavljenic; T K Sampath
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

View more
  3 in total

1.  Endogenous BMP-7 is a critical molecular determinant of the reversibility of obstruction-induced renal injuries.

Authors:  Scott R Manson; Robert A Niederhoff; Keith A Hruska; Paul F Austin
Journal:  Am J Physiol Renal Physiol       Date:  2011-08-31

Review 2.  Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis?

Authors:  Tri Q Nguyen; Roel Goldschmeding
Journal:  Pharm Res       Date:  2008-02-12       Impact factor: 4.200

3.  Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis.

Authors:  Carsten P Bramlage; Björn Tampe; Michael Koziolek; Imad Maatouk; Jelena Bevanda; Peter Bramlage; Katharina Ahrens; Katharina Lange; Holger Schmid; Clemens D Cohen; Matthias Kretzler; Gerhard A Müller
Journal:  BMC Nephrol       Date:  2010-11-16       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.